Sanjay Bhatia

Co-Founder & Managing Director

As the demand-supply gap for vaccines and other lifesaving medicines  continues to widen globally, almost every country has been making significant  investments to strengthen the pharmaceutical ecosystem within their  purview. India has been no different either; owing to numerous government  initiatives such as PLI, PRIP and Make in India, that are aimed at promoting  indigenous manufacturing, the Indian pharma sector currently caters to around 60  percent of the global vaccines demand and emerged as the next global pharma hub in  recent times. As per IMARC Group’s recent report, the Indian vaccines market, which  was valued at $1.49 billion in 2025 is expected to amount to $3.09 billion by 2034,  exhibiting a strong 8.5 percent CAGR during the forecast period.

Standing at the forefront of this dynamic and hyper-competitive industry through its extensive decades long experience of injectable manufacturing is Laborate Pharmaceuticals. Based in Panipat, Laborate was established in 1985 by Ajay Bhatia (Co-Founder & Chairman) and Sanjay Bhatia (Co-Founder & Managing Director) with a vision to add value to the lives of people by making quality healthcare accessible and affordable to all sections of the society.

Today, with a strong footprint across 51 countries in Asia, Africa and the Americas, the company has been recognized as a ‘Three Star Export House’ by the Directorate General of Foreign Trade under the Ministry of Commerce & Industry, Govt. of India – a strong testament to Laborate’s proven mettle at pharmaceutical manufacturing and export at par with international standards.

Laying the Foundation Stone

Back in 1985, India was predominantly dependent on antibiotics, tablets and capsules for treatment, and even the doctors were very much skeptical about giving injectables to their patients. Not only did the country have a severe scarcity of hospitals, nursing homes and other essential healthcare infrastructure to administer injectables, but the process itself was considered an expensive affair that couldn’t be affordable by most patients. During such tumultuous times, Laborate Pharmaceuticals – under the visionary leadership of Sanjay – emerged as the pioneers in the field and started manufacturing injectables, becoming the first company to do so in the entire North India.

Sharing his thoughts on the current market scenario, Sanjay elucidates, “With the recent rollout of the revised Schedule M guidelines, the regulatory landscape in India has become very stringent and the pharma companies too are now extremely conscious about the quality of the entire product manufacturing process. As a result, most manufacturing plants in India are now left with no choice but to upgrade their facilities to remain aligned with the new Schedule M regulations.

While this is a serious challenge to most pharma manufacturers in India, it is a great opportunity for us to capture significant market share since all our facilities audited and certified by numerous international agencies such as WHO GMP, which makes them fully compliant with the new norms”.

Exquisite Range of Products

Under the aegis of Sanjay and Ajay, Laborate has emerged as one of the leading and sought-after names in the pharma manufacturing realm. With over 1500 products in its portfolio, the company’s offerings encompass a wide range of dosage forms that include eye & ear drops, ointments, tablets, sprays & lotions, hard & soft gelatin capsules, injections, dry & liquid syrups, tonics, pregnancy test kits, nutraceuticals, energy drinks, oils, soaps, shampoos, and a lot more. Some of the major brands that it caters to include Festive Dee, Omecap, Ceflox, Icey Cool, Labmox, Fungi-X, Laboclox, Doo Clav, KT5, Clobeta GM, NDS Nflox, Audiclav, Acylab, Labdic, and Oflocin, to name a few. Additionally, Laborate also has two separate divisions for manufacturing its own range of cosmetics and ayurvedic personal care products under the brand names Labolia and Sri Ayurveda, respectively.

“We not only follow Indian, British and US pharmacopoeia across all our injectable products formulation, testing and manufacturing process, but are also a well-established partner in our Prime Minister’s Janaushadhi scheme. Apart from manufacturing, we also provide a wide range of services that include Formulations Development, Bio-studies, Stability Testing, Regulatory Support, Packaging Design & Development, Quality Management, Batches Validation, and many more. Further, we have recently formed a partnership with a German company that has invented a new drug for breast cancer and are currently working with them for their technology transfer and product R&D/F&D”, Sanjay further adds.

State-of-the-Art Facilities for Top-notch Quality

A key highlight of Laborate are its five world-class manufacturing plants that are located in Panipat, Paonta Sahib and Karnal – each approved by over 35 international regulatory bodies such as WHO - Geneva, DPM - Ivory Coast, NAFDAC - Nigeria, SBDMA - Yemen, MOH - Combodia, MOH - Sri Lanka, MOH - Iraq, NDA - Uganda, PPB - Kenya, MOH - Syria, MOH - Malawi, MOH - Sri Lanka, MOH - Tajikistan, MOH - Uzbekistan and MOH - Afghanistan. Equipped with every modern day facility such as chromatography lab, instrument lab, chemical lab, microbiology lab, stability lab and IPQA lab, the company’s manufacturing facilities are fully automated right from the initial production stage to the final packaging of the product under sterile conditions, thus minimizing the risk of any error or contamination. 

All the production units comprise of high capacity German & Chinese machinery that facilitates production of large quantities of products while simultaneously maintaining high quality standards, Overall, Laborate’s per-day production across all its facilities are 200,000 vials, 300,000 ampoules, 300,000 ophthalmic, 200,000 tubes of topical preparations, 300,000 dry injections, 2 million capsules, 15 million tablets, 100,000 bottles of dry syrup, and 100,000 bottles of liquid syrups/emulsions. Additionally, the company also has a full fledged F&D team that is engaged in the development of wide range of dosage forms such as Solid & Liquid orals, creams & ointments, ophthalmic preparations, small volume parenteral, cosmetic formulations, and many more.

“At Laborate, we strongly believe that a product will rule the market only when it conforms to world-class standards and the quality requirement of customers – first time and every time. While our quality control team consists of 150+ highly qualified personnel, including PhD holders, M.Phil and post-graduates, our technical team has been one of the cornerstones of our operations and instrumental in helping us devise formulations & dosage forms for new drugs to be introduced and make variants of particular dosage forms. Most importantly, all our manufacturing plants are headed by highly qualified experts such as Vipulam Mishra, Anil Arora and Murthy, each of whom possesses decades of extensive experience in pharma research and manufacturing”, Sanjay proudly asserts.

Start-Studded Business Journey

Given the industry benchmark practices and exceptional track record that it beholds, Laborate has been conferred with many awards and recognitions – the prominent ones being ‘Udyog Rattan Award’, ‘Emerging India Award’ by ICICI & CNBC (2008) and ‘Excellence Award’ by Institute of Economic Studies (2008). Having very recently received the EU GMP certification to operate across Europe, the company has already received two orders worth Rs.8 crore from the region. Laborate is now looking forward to acquire the Eurasia certification, which is expected to happen by the coming month and enable it to foray into Russia and surrounding countries, followed by approval from the US FDA in the days to come.

“With cancer cases on the rise across India lately, our nation is now being referred to as the cancer capital of the world in recent times. But despite a great demand for injectables and other lifesaving cancer medications, India is still mostly dependent on the import of such medicines from abroad due to the absence of oncology drugs manufacturing capabilities in the country. In light of this, we are now working on installing all the necessary facilities to setup a dedicate oncology unit, which will help the country ward-off reliance on foreign nations and enable us tap into the oncology market”, concludes Sanjay. 

Key Management

Sanjay Bhatia, Co-Founder & Managing Director,  Laborate Pharmaceuticals
• A commerce graduate, Sanjay is a results-driven business leader with extensive cross-functional experience across diverse areas of sales and marketing.

Ajay Bhatia, Co-Founder & Chairman, Laborate Pharmaceuticals
• Holding a bachelor’s degree in pharmaceutical sciences, Ajay is a seasoned pharma industry professional with over four decades of experience in the field. He has been instrumental in driving Laborate’s vision  into reality.

Quick Facts

• Year of Establishment: 1985
• Office Locations: Delhi (headquarter) and Panipat, with five manufacturing plants – one in Panipat (Haryana), three in Paonta Sahib (Himachal Pradesh), and another in Karnal (Haryana)
• Key Product Categories: Injections, Ophthalmic Preparations, Tablets, Capsules, Dry & Liquid Syrups, Topical Preparations, Ayurveda Medicines, and Cosmetics